Cabergoline vs Exemestane
FDA Approved vs FDA Approved
synergistic Mechanism-based · 65% Exemestane supports hormonal recovery from suppression caused by Cabergoline. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life.
Molecular Data
Cabergoline Exemestane
Weight 451.60 Da 296.40 Da
Half-life ~63-69 hours ~24 hours
Type Ergoline-derived dopamine D2 receptor agonist Steroidal aromatase inhibitor (irreversible, suicide inhibitor)
Key Benefits
Cabergoline
01 Potent suppression of prolactin levels, often normalizing them within days
02 Prevents and reverses prolactin-related gynecomastia from 19-nor compounds
03 Restores sexual function impaired by hyperprolactinemia (libido, erectile function, orgasm)
04 Long half-life (63-69 hours) allows convenient twice-weekly dosing
05 Significantly better tolerated than bromocriptine with fewer gastrointestinal side effects
06 Effective at shrinking prolactin-secreting pituitary tumors
07 Low doses required for bodybuilding prolactin management (0.25-0.5mg twice weekly)
Exemestane
01 Irreversible aromatase inactivation eliminates estrogen rebound upon discontinuation
02 Steroidal structure with mild androgenic activity may offset some low-estrogen side effects
03 Potent estrogen suppression (85-95% reduction in estradiol at full dose)
04 Compatible with tamoxifen (unlike anastrozole, no pharmacokinetic interference)
05 Prevents gynecomastia during testosterone or aromatizable steroid cycles
06 Reduces estrogen-driven water retention, bloating, and blood pressure elevation
07 Oral dosing with once-daily or less frequent administration for cycle support
Side Effects
Cabergoline
Nausea (especially during initial doses; mitigated by taking with food)
Dizziness or lightheadedness
Headache
Nasal congestion or stuffiness
Fatigue or drowsiness
Orthostatic hypotension (feeling faint when standing up quickly)
Exemestane
Joint pain and stiffness (generally less severe than with anastrozole due to mild androgenic activity)
Fatigue and general malaise
Hot flashes or flushing
Mood changes (irritability, flat affect, low mood)
Headache
Increased sweating
Contraindications
Known hypersensitivity to cabergoline or any ergot alkaloid
History of cardiac valvular disease or clinically significant valvular regurgitation
History of pulmonary, pericardial, or retroperitoneal fibrotic disorders
Uncontrolled hypertension
Concurrent use of dopamine antagonists (antipsychotics, antiemetics acting on D2 receptors)
Severe hepatic impairment (cabergoline is extensively metabolized by the liver)
Known hypersensitivity to exemestane or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with other aromatase inhibitors (anastrozole, letrozole)
Research Evidence
Cabergoline Exemestane
Status FDA Approved FDA Approved
References 5 studies 5 studies
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.